| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | JW-7-24-1 | GDSC1000 | pan-cancer | AAC | 0.049 | 0.1 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.056 | 0.1 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.054 | 0.1 |
| mRNA | CAY10603 | GDSC1000 | pan-cancer | AAC | 0.049 | 0.1 |
| mRNA | CCT007093 | GDSC1000 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.1 |
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | -0.29 | 0.1 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.07 | 0.1 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | -0.054 | 0.1 |